Pediatric Self-Assessment Program (PEDSAP) Book 2: Oncology and Hematology Disorders (Cert # L249242)

The target Pediatric Self-Assessment Program (PEDSAP) Book 2: Oncology and Hematology is board-certified and advanced level pediatric care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 21.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCPPS.

Oncology and Hematology Disorders I
ACPE #: 0217-9999-24-195-H01-P
Chapter: Chimeric Antigen Receptor T-Cell Therapy

• Assess patient eligibility for chimeric antigen receptor T-cell (CAR-T) therapy based on disease state, comorbidities, and FDA indications, and ability to pay for the therapy.
• Design a supportive care regimen for a patient beginning CAR-T therapy.
• Plan an appropriate lymphodepleting chemotherapy regimen considering patient comorbidities and risk for toxicity.
• Distinguish between immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS) in a patient.
• Develop a plan to monitor, prevent, and treat complications secondary to CRS, ICANS, hemophagocytic lymphohistiocytosis/macrophage activating syndrome, infections, coagulopathies, cytopenias, including B-cell aplasia and graft versus host disease (GVHD).
• Evaluate potential short and long-term complications post-CAR-T therapy and recommend prevention and treatment interventions accordingly.
• Evaluate response to CAR-T therapy and recommend treatment post-CAR-T therapy based on patient-specific response. 

Chapter: Antineoplastic Immunotherapy

• Distinguish between the classes of immunotherapy and how the immune system can be harnessed to target various tumor markers.
• Analyze and detect molecular targets of common pediatric cancers.
• Design an appropriate immunotherapy treatment plan for various pediatric malignancies.
• Assess the risks of immunotherapy and the appropriate treatment of adverse reactions in pediatric patients.
• Evaluate barriers to the uptake of novel antineoplastic immunotherapy treatments in pediatric cancers. 

Oncology and Hematology Disorders II
ACPE #: 0217-9999-24-196-H01-P
Chapter: Pharmacogenomics in Oncology and Hematopoietic Cell Transplant

• Analyze the role of pharmacogenomics in pediatric patients undergoing treatment for cancer or hematopoietic stem cell transplant.
• Evaluate common challenges associated with using pharmacogenomics in routine clinical care.
• Evaluate factors influencing the clinical utility of a pharmacogenomic test and judge when testing is warranted in an individual patient.
• Account for the influence of genomic variation when estimating drug exposure and response.
• Apply the principles of pharmacogenomics to design a patient-specific treatment plan using genomic data.
• Design a plan to advance the use of pharmacogenomics in clinical practice. 

Chapter: Allogeneic Hematopoietic Stem Cell Transplant

• Distinguish the difference in myelosuppression goals for myeloablative and non-myeloablative conditioning regimens.
• Distinguish risk factors for the development of acute graft-versus-host disease (aGvHD).
• Devise an initial treatment plan for a patient with aGvHD.
• Assess patient criteria for the diagnosis of sinusoidal obstructive syndrome/veno-occlusive disease following allogeneic hematopoietic stem cell transplantation (alloHSCT) based on the European Society for Blood and Marrow Transplantation criteria.
• Construct a treatment and monitoring plan for a patient with transplant-associated thrombotic microangiopathy.
• Construct an antimicrobial prophylaxis regimen for a patient undergoing an alloHSCT. 

Oncology and Hematology Disorders III
ACPE #: 0217-9999-24-197-H01-P
Chapter: Immune Thrombocytopenia

• Distinguish the difference between various immune thrombocytopenia (ITP) definitions (e.g., pediatric vs. adult ITP, primary vs. secondary ITP, stages of disease).
• Evaluate the initial management of newly diagnosed ITP patients based on guideline recommendations.
• Design an initial pharmacologic regimen for the treatment of a pediatric patient diagnosed with ITP while considering patient-specific factors.
• Devise and adjust a treatment plan for a patient who has refractory ITP.
• Assess the role and place in therapy of novel agents that treat refractory ITP. 

Chapter: Venous Thromboembolism

• Demonstrate understanding of the prevalence and significance of pediatric venous thromboembolism (VTE).
• Analyze key elements of pathophysiology and risk factors uniquely associated with pediatric VTE patients.
• Judge when to recommend VTE prevention in pediatric patients based on best available evidence.
• Detect signs and symptoms of VTE in pediatric patients and potential challenges in diagnosis.
• Design an anticoagulation plan including medication management and duration of therapy.
• Evaluate the risk of adverse events and the use of reversal agents available in the setting of major bleeding.
• Discover the benefits of pharmacist involvement in pediatric anticoagulation stewardship. 

Oncology and Hematology Disorders IV
ACPE #: 0217-9999-24-198-H01-P
Chapter: Sickle Cell Disease

• Assess therapeutic options for the curative treatment of sickle cell disease (SCD).
• Devise a therapeutic plan for the prevention of vaso-occlusive events in a pediatric patient with SCD.
• Design an antimicrobial prophylaxis and vaccination plan for a patient with SCD.
• Develop management recommendations for acute chest syndrome and vaso-occlusive crisis for pediatric patients with SCD.
• Distinguish when to initiate health screening for pediatric patients with SCD. 

Case Series: Blood Disorders

• Distinguish among different severity levels of hemophilia using laboratory results.
• Design a treatment plan for a patient with severe hemophilia A or B, including prophylaxis and an on-demand plan of care.
• Devise a treatment plan for a patient with hemophilia with inhibitors using alternative therapies.
• Classify von Willebrand disease (VWD) laboratory results with the associated subtype of VWD.
• Assess the differences in VWD treatments and which are appropriate for each type of VWD. 

Oncology and Hematology Disorders V
ACPE #: 0217-9999-24-199-H01-P
Case Series: Supportive Care

• Construct a preventive care plan that effectively and safely addresses patients’ nausea and vomiting on the basis of their initial chemotherapy.
• Assess the emetogenicity of a chemotherapy regimen and when to escalate antiemetics according to the latest chemotherapy-induced nausea and vomiting guidelines.
• Design a therapeutic plan for a patient who has anticipatory nausea and vomiting.
• Evaluate a patient’s risk of procedural pain, and assess the level of sedation required for the procedure.
• Develop a treatment plan for a patient’s procedure considering the patient’s need for sedation and pain control. 

Case Series: Vaccinations in Immunocompromised Patients

• Assess a patient after transplantation or chimeric antigen receptor T-cell (CAR-T) therapy for appropriateness to initiate revaccination.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

• Consultancies: Lauren Campanella (Sanofi); Austyn Grim (Sobi, Inc.); Tina Gu (Servier); Alexis Kuhn (Jazz Pharmaceuticals; Sanofi Genzyme); Ingrid Pan (Sobi Pharmaceuticals); Teresa J. Rushing (Jazz Pharmaceuticals)
• Stock Ownership: Sara Hovey (AbbVie)
• Grants: Dave Procaccini (Grifols Pharmaceutical Co.)
• Honoraria: Lauren Campanella (Novo Nordisk); Kimberly Cheng (Amgen); Allyson Thrall (BTG Pharmaceuticals)
• Other: Timothy W. Jacobs (owner, independent retail pharmacy)

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on pediatric pharmacy activities.